Cancer patients are a unique population with specialised needs. There is compelling evidence that infection in cancer patients remains a leading cause of death and a significant cost to the healthcare system.
Our research group aims to optimise patient outcomes using a health services approach to prevent and manage the critical and growing problems of healthcare associated and antibiotic resistant infection, poor sepsis and antimicrobial management and late recognition of infection in this vulnerable population.
Our work focusses on establishing a national infrastructure for cancer specific infection surveillance, implementation of life saving and harm minimising clinical care pathways for the management of neutropenic fever and sepsis in adults and children and introducing innovative technologies to support the detection of and improve care of infections in cancer. This group comprises experienced translational researchers with national and international profiles in the surveillance and management of infections in cancer.